DOCS vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 13. 1% for Doximity, Inc. (DOCS). Doximity, Inc. (DOCS) offers the better valuation at 20. 4x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Doximity, Inc. (DOCS) a "Hold" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Doximity, Inc.

(DOCS) is the cheapest at 20. 4x versus Hims & Hers Health, Inc. at 56. 6x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +136. 4%, compared to -62. 2% for Doximity, Inc. (DOCS). Over 10 years, the gap is even starker: HIMS returned +194. 6% versus DOCS's -62. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Doximity, Inc.

(DOCS) is the lower-risk stock at 0. 80β versus Hims & Hers Health, Inc. 's 2. 53β — meaning HIMS is approximately 217% more volatile than DOCS relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 13. 1% for Doximity, Inc. (DOCS). On earnings-per-share growth, the picture is similar: Hims & Hers Health, Inc. grew EPS -3. 8% year-over-year, compared to -11. 7% for Doximity, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Doximity, Inc.

(DOCS) is the more profitable company, earning 30. 4% net margin versus 5. 5% for Hims & Hers Health, Inc. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus 4. 5% for HIMS. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DOCS: 47.

2% to $29. 47.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Doximity, Inc.

(DOCS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 53 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DOCS: -62. 2%, HIMS: +194. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DOCS is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.